ReviewInternational journal of molecular sciences2026
Diversity and Multi-Target Potential of Pyrazole, Imidazole or Triazole Derivatives in Modern Anticancer Therapy.
Review in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular insights into triazole-based compounds for triple-negative breast cancer treatment.Journal of enzyme inhibition and medicinal chemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancers are intricate and multifactorial diseases. Despite progress in medicine, there are still some obstacles in their treatment due to drug resistance, the toxicity of combination therapy and lack of drug selectivity toward cancer cells. The solution to this may be multi-target directed ligands (MTDLs), which have gained more and more popularity over the years. This review presents a comprehensive overview of novel potential multi-targeted derivatives of nitrogen-containing heterocycles, as imidazole, pyrazole, 1,2,3-triazole and 1,2,4-triazole. The review gathers the selected literature from 2006 to 2026. The analysis focuses on the potency of the inhibitory activity of selected molecules against a variety of molecular targets, as well as on their interactions with protein binding sites. Additionally, the structure-activity relationship (SAR) studies within the collected series are included. The discussion may contribute to the development of new multi-target anticancer agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.